Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma

Area of Science:

• Hepatocellular Carcinoma (HCC) Pathogenesis
• Targeted Cancer Therapy
• Molecular Oncology

Background:

• Aberrant c-Met signaling is a key driver in hepatocellular carcinoma (HCC) development.
• Previous trials with nonselective kinase inhibitors targeting c-Met in HCC yielded disappointing results.
• Potential reasons for prior failures include suboptimal trial design and off-target effects of nonselective inhibitors.

Purpose of the Study:

• To evaluate the therapeutic potential of selective c-Met inhibitors in hepatocellular carcinoma (HCC).
• To address the limitations of previous clinical trials involving nonselective c-Met inhibitors.
• To explore the efficacy and safety of novel c-Met inhibitors in HCC patients.

Main Methods:

• Review of clinical trial data for nonselective and selective c-Met inhibitors in HCC.
• Analysis of factors contributing to the efficacy and safety of c-Met inhibition.
• Examination of ongoing clinical trial designs for selective c-Met inhibitors in HCC.

Main Results:

• Nonselective c-Met inhibitors showed limited efficacy in HCC, likely due to off-target activity and trial design.
• Selective c-Met inhibitors (tepotinib, capmatinib) can achieve complete c-Met inhibition.
• Preliminary data indicate antitumor activity and acceptable safety for selective c-Met inhibitors in Child-Pugh A HCC patients.

Conclusions:

• Selective c-Met inhibition represents a promising therapeutic strategy for HCC.
• Optimized trial designs incorporating patient selection based on c-Met status are crucial.
• Ongoing clinical trials are poised to further elucidate the benefits of selective c-Met inhibitors in HCC.